针对皮质类固醇耐药性免疫检查点抑制剂诱导的心肌炎的额外免疫抑制药物的有效性:两个病例报告
Hiroyuki Sakaguchi1, Shigeki Nanjo2, Shigeki Sato1
1Department of Medical Oncology, Kanazawa University Hospital, Japan.
Internal medicine (Tokyo, Japan)
|September 4, 2024
概括
免疫检查点抑制剂 (ICI) 可以导致心肌炎,一种严重的心脏病. 对于ICI诱导的对类固醇耐药性心肌炎,添加其他免疫抑制剂,如IVIG和tacrolimus可能是有效的.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 心脏病学 心脏病学
背景情况:
- 免疫检查点抑制剂 (ICI) 在癌症治疗中至关重要,提高了患者的治疗结果.
- 然而,ICI可以引发与免疫相关的不良事件,特别是心肌炎,一种罕见但严重的心脏并发症.
- 由于其潜在的危及生命的性质,ICI诱导的心肌炎构成了重大的临床挑战.
研究的目的:
- 报告两例免疫检查点抑制剂诱导的心肌炎的病例,这些病例对皮质类固醇治疗不耐药.
- 突出额外的免疫抑制疗法在管理耐火性ICI诱导心肌炎的疗效.
- 建议治疗皮质类固醇耐药性ICI诱导心肌炎的方法.
主要方法:
- 两名患者的病例报告经历了ICI诱导的心肌炎.
- 对标准皮质类固醇治疗的治疗耐药性的文件.
- 给予其他免疫抑制剂,包括静脉注射免疫球蛋白 (IVIG) 和塔克罗利斯.
主要成果:
- 这两种报告的病例都显示出皮质类固醇耐药性免疫检查点抑制剂诱导的心肌炎.
- 加上静脉注射的免疫球蛋白和塔克罗利斯,使得这两位患者的心肌炎的成功解决.
- 这些发现表明,早期整合替代性免疫抑制剂可能有好处.
结论:
- 免疫检查点抑制剂诱导的心肌炎可能对皮质类固醇耐药.
- 迅速添加其他免疫抑制疗法,如IVIG和tacrolimus,是耐火病例的可行策略.
- 这种方法可以改善ICI诱导的严重心肌炎患者的结果.
更多相关视频
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
228
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
228
01:26Heart Failure Drugs: Inotropic Agents
545
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
545
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:29Inflammatory Bowel Disease IV: Pharmacological Management
122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
122